作者: Zhi Hong Meng , Alisa S. Wolberg , Dougald M. Monroe , Maureane Hoffman
DOI: 10.1097/01.TA.0000066184.20808.A5
关键词:
摘要: Background Recombinant coagulation factor VIIa (FVIIa) is approved for treating hemophiliacs with inhibitors. High-dose FVIIa has also been used off-label to manage hemorrhage in …